GUMDROP : JHMI J1078 A Phase 2 Randomized Study of Cediranib Alone Compared with the Combination of Cediranib plus Dasatinib in Docetaxel Resistant, Castration Resistant Prostate Cancer

Created by Channing Paller, last modified on Apr 14, 2012

Description:

CRPC with prior hormonal therapy; PD on or after docetaxel therapy; no maximum prior therapy; NO prior angiogenesis or Src or FAK inhibitors

Link:

http://clinicaltrials.gov/ct2/show/NCT01260688

Site:

Johns Hopkins Hospital

Principal Investigator:

Michael Carducci, M.D.